Drug Trial Radar · NCT06352138
Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients
Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Jul 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- MegalabsIndustry
- Sponsor type
- Industry
- First posted
- Apr 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III, multicentre, double-blind, randomised, parallel, equivalence clinical trial to determine the efficacy, safety and immunogenicity of Megalabs® recombinant human alfa epoetin for intravenous use, compared to Epogen®, in the treatment of anaemia in participants with chronic renal disease, dependent on haemodialysis
Conditions
- Anemia of Chronic Kidney Disease
Interventions
Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.Biological
comparison vs the reference product to demonstrate biological similarity
Active comparator: European Union licenced epoetin alfaBiological
comparison vs. the test product to demonstrate biological similarity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Absolute Change in Hemoglobin LevelsTime frame: 18 months
- Change in Mean Hb LevelTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Megalabs
Colonia Nicolich, Departamento de Canelones, Uruguay
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.